Page last updated: 2024-11-12
2'-methoxykurarinone
Description
2'-methoxykurarinone: cytotoxic lavandulyl flavanone from Sophora flavescens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(2S)-2'-methoxykurarinone : A dimethoxyflavanone that is (2S)-(-)-kurarinone in which the hydroxy group at position 2' is replaced by a methoxy group. Isolated from the roots of Sophora flavescens, it exhibits cytotoxicity against human myeloid leukemia HL-60 cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Sophora | genus | A plant genus of the family FABACEAE.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| Sophora flavescens | species | [no description available] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
Cross-References
Synonyms (20)
| Synonym |
|---|
| (2s)-7,4'-dihydroxy-8-lavandulyl-5,2'-dimethoxyflavanone |
| LMPK12140500 |
| (2s)-2'-methoxykurarinone |
| CHEMBL496451 , |
| chebi:66151 , |
| (2s)-2'-methoxy kurarinone |
| (2s)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydro-4h-chromen-4-one |
| 7,4'-dihydroxy-5,2'-dimethoxy-8-lavandulylflavanone |
| bdbm50377944 |
| 270249-38-2 |
| 2'-methoxykurarinone |
| 2'-o-methylkurarinone |
| kurarinone, 2'-o-methyl- |
| AKOS032962578 |
| Q27134673 |
| (2s)-7-hydroxy-2-(4-hydroxy-2-methoxyphenyl)-5-methoxy-8-[(2r)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one |
| HY-N1746 |
| CS-0017422 |
| MS-28230 |
| GLXC-14149 |
Roles (2)
| Role | Description |
|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| dimethoxyflavanone | A methoxyflavanone that is flavanone with two methoxy substituents. |
| dihydroxyflavanone | Any hydroxyflavanone carrying two hydroxy substituents. |
| 4'-hydroxyflavanones | Any hydroxyflavanone having a hydroxy substituent located at position 4'. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
Biological Processes (16)
Molecular Functions (8)
Ceullar Components (20)
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID344054 | Inhibition of human BACE1 | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
| BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID380063 | Cytotoxicity against human HL60 cells after 96 hrs by MTT assay | 2000 | Journal of natural products, May, Volume: 63, Issue:5
| Cytotoxic lavandulyl flavanones from Sophora flavescens. |
| AID344052 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPalpha level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
| BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| AID344053 | Inhibition of human BACE1 expressed in HEK293 cells assessed as reduction in soluble APPbeta level after 4 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
| BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.82 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.77 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |